Mental Health Documentation: Latuda Isn’t Approved For The Treatment Of Patients With Dementia-Related Psychosis

Potential for Cognitive and Motor Impairment. Patients going to be cautioned about operating hazardous machinery, including motor vehicles, until they are reasonably certain that therapy with LATUDA does not affect them adversely. Now look, the proportion of female patients with prolactin elevations ≥5x ULN was 7percentage for ‘LATUDA treated’ patients versus 0 for ‘placebotreated’ female patients. In the short term, placebo controlled studies, the median change from baseline to endpoint in prolactin levels for ‘LATUDAtreated’ females was -2 ng/mL and was 5 ng/mL for males. Basically the proportion of male patients with prolactin elevations ≥5x ULN was 6 for LATUDA treated patients versus 6 for placebo treated male patients. NMS can cause hyperpyrexia, muscle rigidity, altered mental status and evidence of autonomic instability. Consequently, additional signs may include elevated creatine phosphokinase, myoglobinuria, and acute renal failure. NMS, a potentially fatal symptom complex, had been reported with administration of antipsychotic drugs, including LATUDA. Management should include immediate discontinuation of antipsychotic drugs and identical drugs not essential to concurrent therapy, intensive symptomatic treatment and medical monitoring, and treatment ain’t approved for the treatment of patients with dementiarelated psychosis. TD is a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements that can develop in patients with antipsychotic drugs. Albeit the syndrome may remit, So there’s no known treatment for established cases of TD, partially or completely, Therefore in case antipsychotic treatment is withdrawn. That’s right! Although much less commonly, the syndrome can develop, after relatively brief treatment periods at low doses. Given these considerations, LATUDA gonna be prescribed in a manner that is most certainly to minimize the occurrence of TD. Risk of developing TD and the likelihood that it shall be irreversible are believed to increase as the duration of treatment and the tal cumulative dose of antipsychotic drugs administered to the patient increase.

Drug discontinuation going to be considered, if signs and symptoms appear in a patient on LATUDA. Tardive Dyskinesia. He is the Bipolar Disorder Section Editor for Psychiatric Times. Full bio here. James Phelps, MD is Director of the Mood Disorders Program at Samaritan Mental Health in Corvallis. LATUDA may cause orthostatic hypotension. Orthostatic Hypotension and Syncope. Orthostatic vital signs will be monitored in patients who are vulnerable to hypotension, in patients with known cardiovascular disease or history of cerebrovascular disease and in patients who are antipsychoticnave. Now regarding the aforementioned fact… Disruption of the body’s ability to reduce core body temperature was attributed to antipsychotic agents. Body Temperature Regulation. Whenever exercising strenuously, exposure to extreme heat, receiving concomitant medication with anticholinergic activity, or being subject to dehydration, appropriate care is advised when prescribing LATUDA for patients who gonna be experiencing conditions that may contribute to an elevation in core body temperature.

In the shortterm, ‘placebocontrolled’ monotherapy study, the median change from baseline to endpoint in prolactin levels for LATUDA treated females was 1 ng/mL and was 5 ng/mL for males.

In the short term, placebocontrolled adjunctive therapy with lithium or valproate study, the median change from baseline to endpoint in prolactin levels for LATUDA treated females was 2 ng/mL and was 4 ng/mL for males.

Then the proportion of female patients with prolactin elevations ≥5x ULN was 0percent for ‘LATUDA treated’ patients versus 0percent for placebo treated female patients. Now look, the proportion of male patients with prolactin elevations ≥5x ULN was 0percent for LATUDAtreated patients versus 0 for placebotreated male patients. Then the proportion of female patients with prolactin elevations ≥5x ULN was 6 for LATUDA treated patients versus 0percent for placebo treated female patients. Nevertheless, the proportion of male patients with prolactin elevations ≥5x ULN was 0percent for LATUDA treated patients versus 0 for ‘placebo treated’ male patients. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics should undergo fasting blood glucose testing.